RE:RE:more BET publications and new indications?"
If we are to believe the latest December 2018, Corporate Presentation, the third party adjudication is anticipated 2 to 3 months past trial completion. Trial completion being H1, 2019. So does that not mean that adjudication does not run concurrently with any part of the ongoing trial? Adjudication follows trial completion and not before. Adjudication will likely end in early part of Q3, 2019 and topline results following that." The only concrete changes that have occured between the Sept 12 AGM and the latest December Corporate update and MD&A are: 1) Last dosing
was expected by end of year but
now pushed into 2019; and 2) Adjudication of all events
was stated as 2 months but
now stated as 2-3 months. Technically, the difference between end of 2018 and beginning of 2019 for end of dosing is arbitrary, as we will all observe tomorrow night. After dosing ends, very likely patient follow up visits and adjudication happen concurrently during that 2-3 month period, though it could be up to 4 months in my opinion since every BETonMACE trial slide/poster, including the latest from
AHA Nov 2018, has indicated a 4-16 week follow up period. Based on latest available info, the earliest case scenario is dosing ends Jan 2019 and adjudication ends March 2019. But of course a later H1 2019 end of dosing and a longer follow up/adjudication period pushes this out. Still possible for end of dosing, completion of follow up/adjudication, release of top-line and presentation of full data to ALL occur in H1 2019 if the stars align. More clarity to come Monday afternoon Jan 7th at Biotech Showcase.
BearDownAZ